What Clover Health Investments (CLOV) Said on Its Q3 Earnings Call

Clover Health (CLOV) reported Q3 2026 revenue of $2.3B (+57% YoY) and net income of $62M (+$98M YoY). Membership grew 49% YoY to 157,000. The company expects continued growth and improved member economics, with higher gross profit per member over time. CLOV has no debt and $513M in cash. Management is optimistic about 2027 membership growth and AI-driven operational improvements.

Original reporting

finance.yahoo.com

Published Nov 5, 2026, 1:14 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 5, 2026, 1:23 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

What Clover Health Investments (CLOV) Said on Its Q3 Earnings Call — source image — Source · finance.yahoo.com

Decision brief

The 30-second read

$CLOVBullishMed

Why it matters

The disclosed earnings beat and cash strength are likely to drive a short‑term rally, while guidance uncertainty for 2027 may limit upside.

Market read

First disclosure of Q3 results for a mid‑cap health‑tech insurer; material earnings data and membership growth are new and actionable.

What to watch

Potential regulatory risk from pending government appeal and competitive pressure in core markets.

Relevance 7/10Novelty 7/10Timing: after-hours

Background

Clover Health reported its Q3 2026 earnings, detailing membership growth, revenue, profitability, and strategic focus on AI‑driven care.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CLOVBullishHigh confidence

Context

Q3 earnings disclosed revenue up 57% to $2.3B, net income $62M and membership growth 49% YoY.

Expected impact

likely upward pressure as investors price in higher revenue and cash balance, tempered by short-term earnings drag.

Evidence & confidence

First report of Q3 results with material revenue increase and cash position; market typically reacts positively to such earnings beats.

Market effects

Sector

Highlights growth potential in Medicare Advantage and health‑tech sector, may boost peer valuations.

Regional

Positive for U.S. healthcare insurers focusing on technology‑enabled care.

Global

Limited to U.S. market; no direct global impact.

Counterpoint

What could challenge this read

New member onboarding could suppress near‑term earnings, prompting a short‑term pullback.

Key entities

company
Clover Health Investments
U.S. Medicare Advantage insurer and health‑tech provider.
executive
Andrew Toy
CEO of Clover Health, provided commentary on star ratings and AI initiatives.

Read at source ← All news

$CLOVLow

Clover Health (CLOV) Gains 9% After-Hours as Managed Care Names Rally

Clover Health (CLOV) rose 9% in after-hours trading to $4.82, following a broader rally in managed care stocks. Humana's Q3 2026 earnings report drove sector gains, with Humana up 4.61% during regular trading. Clover's move outpaced peers like CVS Health and Elevance Health.

247wallst.comNov 6

$CLOVHighAI 8/10

Clover Health 3Q 2026: Revenue $759.3M, EPS $0.01 — 10-Q Summary

Clover Health reported 3Q 2026 revenue of $759.3M, up 53% YoY, and net income of $6.44M, reversing a prior-year loss. Growth was driven by Medicare Advantage membership and higher premiums, but offset by increased medical and administrative costs. EPS was $0.01.

tradingview.comNov 6

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.

finance.yahoo.comNov 5

$CLOVHigh

Needham reiterates Clover Health stock rating on profitability

Needham maintained a Buy rating and $6.00 price target for Clover Health (CLOV), citing its path to GAAP profitability in 2026. The company reported Q3 2026 earnings of $0.01 per share, beating estimates, with revenue at $759.3M. Needham highlighted strong cohort economics and growth prospects, but noted risks like valuation and medical cost trends.

investing.comNov 5

$CLOVMed

CLOV: Revenue and profitability strengthened as FY26 guidance rose across all listed metrics

Clover Health Investments reported 3Q26 revenue growth of 53% YoY, with GAAP net income of $6M and Adjusted EBITDA of $16M. The company raised its FY26 guidance across all metrics, citing strong MA membership growth and a leading PPO quality rating, according to its slides release.

tradingview.comNov 4